Hossein Borghaei, DO, MS
Dr. Borghaei is a medical oncologist and specialist in the treatment of lung cancer and malignant pleural mesothelioma at Fox Chase Cancer Center in Philadelphia, Pennsylvania. He holds the positions of Chief of Thoracic Medical Oncology, Professor in The Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies.
Dr. Borghaei makes use of innovative and novel treatments for lung cancer, including the use of immunotherapy and targeted therapies. He values the multidisciplinary approach to treating cancer at Fox Chase and appreciates the ability to work with his patients in a place where great care is delivered in a personal and supportive way. He believes in treating patients as an individual with a disease rather than simply treating the disease, and engaging with them and their families.[1]
Education and Career
Dr. Borghaei earned his Doctor of Osteopathic Medicine degree at the Philadelphia College of Osteopathic Medicine. He completed his internship and residency in Internal Medicine at Graduate Hospital and then completed a fellowship training in Hematology and Oncology at Fox Chase Cancer Center. After completing his fellowship, he chose to stay at Fox Chase because he believed in its mission.[1]
Professional Memberships, Activities, and Awards
Dr. Borghaei is a member of the Lung Cancer Expert Medical Advisory Panel of the American Lung Association and a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG). He has previously served as a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel and has been the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award.[2]
Dr. Borghaei is a past recipient of the Robert Krigel Teaching Award at Fox Chase Cancer Center for his contributions to the hospital’s fellowship program and also chairs the facility’s Research Review Committee.[2]
Research
Dr. Borghaei’s laboratory focuses on monoclonal antibodies, targeted therapies, immunotherapy, and cancer vaccines. He is an active participant in top clinical trials that directly address his patients’ needs and help advance the field of lung cancer therapy. The lab has been able to create new monoclonal antibodies against various cancer-related targets and has already received a patent for one of them.[1]
Dr. Borghaei also collaborates with scientists beyond the walls of Fox Chase to bring newer and more effective immune-based treatments to his patients. Much of his investigation is dedicated to understanding why certain patient’s tumors respond to a treatment while others don’t.
Dr. Borghaei has authored and co-authored over 300 articles that have been published in respected medical journals. Some of his publications include:[1]
Borghaei H., Redman M.W., Kelly K., Waqar S.N., Robert F., Kiefer G.J., Stella P.J., Minichiello K., Gandara D.R., Herbst R.S., Papadimitrakopoulou V.A., Swog s1400a (nct02154490): A phase ii study of durvalumab for patients with previously treated stage iv or recurrent squamous cell lung cancer (lung-map sub-study). Clin Lung Cancer. 22(3): 178-186, 2021.PMC8686189. https://www.ncbi.nlm.nih.gov/pubmed/33358401.
Borghaei H., Gettinger S., Vokes E.E., Chow L.Q.M., Burgio M.A., de Castro Carpeno J., Pluzanski A., Arrieta O., Frontera O.A., Chiari R., Butts C., Wójcik-Tomaszewska J., Coudert B., Garassino M.C., Ready N., Felip E., García M.A., Waterhouse D., Domine M., Barlesi F., Antonia S., Wohlleber M., Gerber D.E., Czyzewicz G., Spigel D.R., Crino L., Eberhardt W.E.E., Li A., Marimuthu S., Brahmer J., Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 39(7): 723-733 2021.PMC8078445. https://www.ncbi.nlm.nih.gov/pubmed/33449799.
Judd J., Abdel Karim N., Khan H., Naqash A.R., Baca Y., Xiu J., VanderWalde A.M., Mamdani H., Raez L.E., Nagasaka M., Pai S.G., Socinski M.A., Nieva J.J., Kim C., Wozniak A.J., Ikpeazu C., de Lima Lopes G., Jr., Spira A.I., Korn W.M., Kim E.S., Liu S.V., Borghaei H., Characterization of kras mutation subtypes in non-small cell lung cancer. Mol Cancer Ther. 20(12): 2577-2584, 2021. https://www.ncbi.nlm.nih.gov/pubmed/34518295.
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller S, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer, 2018. PubMed
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I dose escalation, pharmacokinetic, and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23. PubMed
Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007;30:455-467. PubMed
